JSA Advises Advent International

JSA advised Advent International and Suven Pharmaceuticals Limited, which is listed in India, in the ~USD 3 billion dollar (combined) merger of Cohance Lifesciences Limited with and into Suven Pharmaceuticals Limited, as one of the largest transactions of its kind.

Following the merger, Suven Pharmaceuticals Limited has now been renamed as Cohance Lifesciences Limited.

JSA transaction team was led by Partner & National Corporate Lead, Iqbal Khan & Partner, Ambarish with support from Principal Associate, Krishaal Morjaria, Senior Associate, Tarini Sardesai & Associates Ayushi Choudhary and Raviraj Zinzuvadia.

Deal value — ~USD 3 billion.

Must Watch

maintenance to second wife

bail in false pretext of marriage

right to procreate of convict

Criminology, Penology and Victimology book release

Join the discussion

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.